Induction of fibronectin by HER2 overexpression triggers adhesion and invasion of breast cancer cells

Experimental Cell Research

Volumn 333, Issue 1, 2015, Pages 116-126

  Jeon, Myeongjin ^a,b   Lee, Jeongmin ^a   Nam, S J ^a   Shin, Incheol ^c   Lee, J E ^a,b   Kim, Sangmin ^a  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

Adhesion; Fibronectin; HER2; Invasion; Trastuzumab

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER CELL LINE; CELL ADHESION; CELL INVASION; CELL STRUCTURE; CONTROLLED STUDY; GENE; HER2 GENE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; CELL SHAPE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR CELL LINE; TUMOR INVASION;

BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL SHAPE; EPIDERMAL GROWTH FACTOR; FEMALE; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2; TRANSCRIPTIONAL ACTIVATION; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 84926420659     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2015.02.019     Document Type: Article

References (34)

1. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001, 61(Suppl 2):S1-S13.
2. Schechter A.L., Stern D.F., Vaidyanathan L., Decker S.J., Drebin J.A., Greene M.I., Weinberg R.A. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984, 312:513-516.
3. Nunes R.A., Harris L.N. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin. Breast Cancer 2002, 3:125-135. discussion 136-127.
4. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19:3159-3167.
5. Brennan P.J., Kumagai T., Berezov A., Murali R., Greene M.I. HER2/neu: mechanisms of dimerization/oligomerization. Oncogene 2000, 19:6093-6101.
6. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1673-1684.
7. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
8. Kim S., Choi J.H., Lim H.I., Lee S.K., Kim W.W., Cho S., Kim J.S., Kim J.H., Choe J.H., Nam S.J., Lee J.E., Yang J.H. EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line. Cell. Signal. 2009, 21:892-898.
9. Kim S., Han J., Lee S.K., Koo M., Cho D.H., Bae S.Y., Choi M.Y., Kim J.S., Kim J.H., Choe J.H., Yang J.H., Nam S.J., Lee J.E. Smad7 acts as a negative regulator of the epidermal growth factor (EGF) signaling pathway in breast cancer cells. Cancer Lett. 2012, 31l:147-154.
10. Gupta P., Srivastava S.K. HER2 mediated de novo production of TGFbeta leads to SNAIL driven epithelial-to-mesenchymal transition and metastasis of breast cancer. Mol. Oncol. 2014, 8(8):1532-1547.
11. Cheng J.C., Qiu X., Chang H.M., Leung P.C. HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells. Biochem. Biophys. Res. Commun. 2013, 434:81-86.
12. Pankov R., Yamada K.M. Fibronectin at a glance. J. Cell Sci. 2002, 115:3861-3863.
13. Ritzenthaler J.D., Han S., Roman J. Stimulation of lung carcinoma cell growth by fibronectin-integrin signalling. Mol. bioSyst. 2008, 4:1160-1169.
14. Fernandez-Garcia B., Eiro N., Marin L., Gonzalez-Reyes S., Gonzalez L.O., Lamelas M.L., Vizoso F.J. Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis. Histopathology 2014, 64:512-522.
15. Bae Y.K., Kim A., Kim M.K., Choi J.E., Kang S.H., Lee S.J. Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer. Hum. Pathol. 2013, 44:2028-2037.
16. Pytela R., Pierschbacher M.D., Ruoslahti E. Identification and isolation of a 140kd cell surface glycoprotein with properties expected of a fibronectin receptor. Cell 1985, 40:191-198.
17. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992, 69:11-25.
18. Guan J.L. Role of focal adhesion kinase in integrin signaling. Int. J. Biochem. Cell Biol. 1997, 29:1085-1096.
19. Owens L.V., Xu L., Craven R.J., Dent G.A., Weiner T.M., Kornberg L., Liu E.T., Cance W.G. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res. 1995, 55:2752-2755.
20. Moasser M.M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26:6469-6487.
21. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J. Clin. Oncol. 2009, 27:5278-5286.
22. Chung S.S., Giehl N., Wu Y., Vadgama J.V. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int. J. Oncol. 2014, 44:403-411.
23. Carpenter R.L., Paw I., Dewhirst M.W., Lo H.W. Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells. Oncogene 2015, 34(5):546-557.
24. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.S., Andersson M., Inbar M., Lichinitser M., Lang I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Ruschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S., Gelber R.D. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1659-1672.
25. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 2007, 357:39-51.
26. Reddy V.S., Harskamp R.E., van Ginkel M.W., Calhoon J., Baisden C.E., Kim I.S., Valente A.J., Chandrasekar B. Interleukin-18 stimulates fibronectin expression in primary human cardiac fibroblasts via PI3K-Akt-dependent NF-kappaB activation. J. Cell. Physiol. 2008, 215:697-707.
27. Uchiyama-Tanaka Y., Matsubara H., Mori Y., Kosaki A., Kishimoto N., Amano K., Higashiyama S., Iwasaka T. Involvement of HB-EGF and EGF receptor transactivation in TGF-beta-mediated fibronectin expression in mesangial cells. Kidney Int. 2002, 62:799-808.
28. Hayashida T., Poncelet A.C., Hubchak S.C., Schnaper H.W. TGF-beta1 activates MAP kinase in human mesangial cells: a possible role in collagen expression. Kidney Int. 1999, 56:1710-1720.
29. Kim S., Oh S.J., Lee J., Han J., Jeon M., Jung T., Lee S.K., Bae S.Y., Kim J., Gil W.H., Kim S.W., Lee J.E., Nam S.J. Berberine suppresses TPA-induced fibronectin expression through the inhibition of VEGF secretion in breast cancer cells. Cell. Physiol. Biochem. 2013, 32:1541-1550.
30. Helleman J., Jansen M.P., Ruigrok-Ritstier K., van Staveren I.L., Look M.P., Meijer-van Gelder M.E., Sieuwerts A.M., Klijn J.G., Sleijfer S., Foekens J.A., Berns E.M. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin. Cancer Res. 2008, 14:5555-5564.
31. Balanis N., Wendt M.K., Schiemann B.J., Wang Z., Schiemann W.P., Carlin C.R. Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. J. Biol. Chem. 2013, 288:17954-17967.
32. Park J., Schwarzbauer J.E. Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition. Oncogene 2014, 33:1649-1657.
33. Sudo T., Iwaya T., Nishida N., Sawada G., Takahashi Y., Ishibashi M., Shibata K., Fujita H., Shirouzu K., Mori M., Mimori K. Expression of mesenchymal markers vimentin and fibronectin: the clinical significance in esophageal squamous cell carcinoma. Ann. Surg. Oncol. 2013, 20(Suppl 3):S324-S335.
34. Maity G., Choudhury P.R., Sen T., Ganguly K.K., Sil H., Chatterjee A. Culture of human breast cancer cell line (MDA-MB-231) on fibronectin-coated surface induces pro-matrix metalloproteinase-9 expression and activity. Tumour Biol. 2011, 32:129-138.